Cognivia is thrilled to announce the strategic expansion of its subsidiary, Cognivia USA Inc., into the US market. This expansion represents not only a geographical shift but also a strategic alignment with our global vision of advancing clinical research. Cognivia aims to provide sponsors with high-value, risk-free solutions designed to address long-standing challenges in clinical research such as data variability or patient medical adherence, ensuring sponsors can navigate the complexities of the industry with confidence and precision.
Central to Cognivia’s mission is our Machine Learning (ML)-powered platform of solutions, designed to predict patient behaviors and enhance the delivery of patient therapies. Our goal is to empower sponsors to invest in their portfolios with certainty, ensuring that only compounds with genuine efficacy and safety concerns are discontinued. By unlocking critical patient characteristics data, Cognivia helps prevent therapies from failing for the wrong reasons, ultimately ensuring better outcomes for patients.
Cognivia’s contemporary vision emphasizes a patient-centric approach, focusing on inclusivity and flexibility in clinical trials. We are committed to guiding sponsors through the ever-evolving landscape of clinical research, providing them with the tools and insights needed to overcome the challenges of modern clinical trials. Our dedication is to ensure that sponsors can adapt effectively to industry changes, thereby enhancing patient outcomes.
One of the greatest challenges in clinical trials is the variability in patient responses, which can obscure the true efficacy of a therapy. Cognivia’s solution, Placebell, is designed to manage patient heterogeneity and variability in responses, ensuring robust data analysis and interpretation. Our ML-powered technology provides the critical data needed to understand and predict patient responses. This enables sponsors to see through patient differences, increasing the success rates of clinical trials and accelerating the delivery of new therapies to patients.
The landscape of clinical trials is rapidly evolving, with a shift towards remote, hybrid, and mixed-model trials. These new models bring operational challenges such as patient retention and adherence, which are critical for the success of trials. Cognivia’s Compl-AI technology is designed to address these challenges by offering predictive insights and solutions to improve patient engagement and compliance, ensuring successful outcomes in modern clinical research settings. Compl-AI predicts nonadherence and dropout risks, helping clinical trial managers engage participants who need it most to ensure complete study results. Compl-AI combines data about patient traits with an ML-model to create a score that can be used during screening and trial visits to customize support and increase patient retention.
“With the expansion of Cognivia USA Inc. into the US market, we are poised to tackle complex challenges in clinical research and enhance patient outcomes.” stated Dominique Demolle, CEO of Cognivia. “Our pioneering approach to tackling these long-standing challenges makes us unique in minimizing data variability, improving patient engagement, and promoting diversity in clinical trials. We are committed to being a valuable partner in successful compound development, ensuring the accelerated delivery of new therapies to patients without any risk to the sponsor. As Cognivia USA Inc., under the leadership of David Weiss, Cognivia US President, embarks on this journey, we eagerly anticipate collaborating with key players to drive significant advancements in clinical research, elevate clinical trials, and maintain our leadership in advancing healthcare solutions.“